Pharmacokinetics of Huperzine A Oral Solution in Healthy Participants

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
In this study, 4 dose groups are planned: Group 1 (0.22 mg, QD), Group 2 (0.22 mg, BID), Group 3 (0.44 mg, QD), and Group 4 (0.44 mg, BID). Ten healthy study participants will be enrolled in each dose group, and randomized to the investigational drug group or the placebo group in a 4:1 ratio (i.e., 8 study participants in the investigational drug group and 2 study participants in the placebo group). An appropriate gender ratio will be ensured within each dose group.
Epistemonikos ID: 28fa24474a68ac8ad7f08cdae6ddb1a5f41f4144
First added on: Aug 25, 2026